This article is more than 5 years old. Information may no longer be current.

OpGen announces acquisition of AdvanDx

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

OpGen has agreed to acquire AdvanDx, which will be accounted for as a merger combination, the company announced in a press release.

OpGen, whose products include the Acuitas MDRO Gene Test, CR Elite Test, Resistome Test, Whole Genome Sequence Analysis and the Lighthouse MDRO Management System, said that merging with the developer of several FDA-approved advanced molecular diagnostic products would supplement the company’s current market strategy.

“The acquisition of AdvanDx strengthens OpGen’s portfolio of rapid molecular tests for combating drug-resistant infections, while providing additional avenues to sell our Acuitas tests,” Evan Jones, chairman and CEO of OpGen, said in the release. “Combination of the two companies will expand our revenue and customer base and provide rapid testing capabilities to complement our MDRO gene tests. Together we will be able to combine rapid organism ID capabilities with best-in-class drug resistance testing.”